Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Fava, M. Search for Related Content PubMed Citation Articles by Fava, M. Depression Antidepressants Related Articles

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

STAR*D StudyTeam

OBJECTIVE: Few controlled studies have addressed the issue of which antidepressant medications should be recommended for outpatients who have not responded to multiple treatment trials. This study compared the efficacy of switching to mirtazapine to that of switching to a tricyclic antidepressant (nortriptyline) following two prospective, consecutive, unsuccessful medication treatments for nonpsychotic major depressive disorder. METHOD: Following lack of remission or an inability to tolerate an initial trial of citalopram for up to 12 weeks (first step) and a second trial with either monotherapy involving another antidepressant or augmentation of citalopram with bupropion or buspirone (second step), adult outpatients (N=235) with nonpsychotic major depressive disorder were randomly assigned to 14 weeks of treatment with mirtazapine (up to 60 mg/day) (N=114) or nortriptyline (up to 200 mg/day) (N=121). The primary outcome, symptom remission, was defined a priori as a total exit score of 7 on the 17-item Hamilton Rating Scale for Depression. The 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR₁₆), obtained at treatment visits, provided secondary outcomes of remission (score 5 at exit) and response (50% reduction in score from baseline). RESULTS: For mirtazapine, remission rates were 12.3% and 8.0% per the Hamilton and QIDS-SR₁₆ scores, respectively. For nortriptyline, remission rates were 19.8% and 12.4%, respectively. QIDS-SR₁₆ response rates were 13.4% for mirtazapine and 16.5% for nortriptyline. Neither response nor remission rates statistically differed by treatment, nor did these two treatments differ in tolerability or adverse events. CONCLUSIONS: Switching to a third antidepressant monotherapy regimen after two consecutive unsuccessful antidepressant trials resulted in low remission rates (<20%) among patients with major depressive disorder.

Related Articles:

STAR*D: The Results Begin to Roll in

Matthew Menza
Am J Psychiatry 2006 163: 1123. [Full Text] [PDF]

This article has been cited by other articles:

				C. Andreescu, B. H. Mulsant, P. R. Houck, E. M. Whyte, S. Mazumdar, A. Y. Dombrovski, B. G. Pollock, and C. F. Reynolds III Empirically Derived Decision Trees for the Treatment of Late-Life Depression Am J Psychiatry, July 1, 2008; 165(7): 855 - 862. [Abstract] [Full Text] [PDF]

				A. J. Rush MD Developing the evidence for evidence-based practice Can. Med. Assoc. J., May 6, 2008; 178(10): 1313 - 1315. [Full Text] [PDF]

				A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report Focus, January 1, 2008; 6(1): 128 - 142. [Abstract] [Full Text] [PDF]

				D. L Dunner Mirtazapine and nortriptyline similarly effective third-line treatments for depression Evid. Based Ment. Health, February 1, 2007; 10(1): 16 - 16. [Full Text] [PDF]

				A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report Am J Psychiatry, November 1, 2006; 163(11): 1905 - 1917. [Abstract] [Full Text] [PDF]

				Bibliography PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 512. [Full Text] [PDF]

				Abstracts PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 515. [Full Text] [PDF]

				M. Valenstein Keeping Our Eyes on STAR{star}D Focus, September 1, 2006; 4(4): 522. [Full Text] [PDF]

				M. Valenstein Keeping Our Eyes on STAR*D Am J Psychiatry, September 1, 2006; 163(9): 1484 - 1486. [Full Text] [PDF]

				A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. E. Thase, P. J. McGrath, J. E. Alpert, D. Warden, J. F. Luther, G. Niederehe, et al. A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report Am J Psychiatry, September 1, 2006; 163(9): 1519 - 1530. [Abstract] [Full Text] [PDF]

				P. J. McGrath, J. W. Stewart, M. Fava, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, M. E. Thase, L. Davis, M. M. Biggs, K. Shores-Wilson, et al. Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report Am J Psychiatry, September 1, 2006; 163(9): 1531 - 1541. [Abstract] [Full Text] [PDF]

				More Results from a Large Antidepressant Trial Journal Watch (General), August 10, 2006; 2006(810): 4 - 4. [Full Text]

				After Two Failed Trials for Major Nonpsychotic Depression, What's Next? Journal Watch Psychiatry, July 17, 2006; 2006(717): 1 - 1. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us